![Diane Young](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Diane Young
Chief Tech/Sci/R&D Officer at
CELLDEX THERAPEUTICS, INC.
Net worth: 636 849 $ as of 2026-06-29
Profile
Diane C.
Young is currently Chief Medical Officer & Senior Vice President at Celldex Therapeutics, Inc. since 2019 and serves as a Trustee at The Valerie Fund.
Former positions include Assistant Director-Clinical Investigation II at Hoffmann-La Roche, Inc. from 1988 to 1990; Director-Clinical Research at Sandoz Research Institute from 1991 to 1993; Vice President-Global Development at R.W.
Johnson Pharmaceutical Research Institute from 1992 to 2002; Chief Medical Officer & Vice President at GTx, Inc. from 2015 to 2019; and Head-Oncology Clinical Development at Novartis Oncology, Inc. Education includes undergraduate studies at Harvard University and a doctorate from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-24 | 17,115 ( 0.02% ) | 636 849 $ | 2026-06-29 |
Diane Young active positions
| Companies | Position | Start |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-07-07 |
The Valerie Fund
 The Valerie Fund Miscellaneous Commercial ServicesCommercial Services Provides children health care services for the children who are suffering with cancer | Director/Board Member | - |
Former positions of Diane Young
| Companies | Position | End |
|---|---|---|
GTx, Inc.
 GTx, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of small molecules for the treatment of cancer | Chief Tech/Sci/R&D Officer | 2019-01-31 |
R.W. Johnson Pharmaceutical Research Institute | Corporate Officer/Principal | 2002-10-31 |
Sandoz Research Institute | Corporate Officer/Principal | 1992-12-31 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | 1989-12-31 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | - |
Training of Diane Young
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
30
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of small molecules for the treatment of cancer | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
R.W. Johnson Pharmaceutical Research Institute | |
Sandoz Research Institute | |
Celldex Therapeutics, Inc.
 Celldex Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes immunotherapy technologies for the treatment of cancer and other diseases | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Valerie Fund
The Valerie Fund Miscellaneous Commercial ServicesCommercial Services Provides children health care services for the children who are suffering with cancer | Commercial Services |
- Stock Market
- Insiders
- Diane Young
